This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Wednesday, May 18, 2016
"Pay For Performance" Drug Plans Could Impact Biopharma's R&D Priorities
"Pay For Performance" Drug Plans Could Impact Biopharma's R&D Priorities John LaMattina , Contributor
As healthcare costs continue to rise, payers are seeking ways to get prices under control. One method gaining more and more favor when it comes to paying for new, expensive medicines is pay-for-performance – an arrangement where a payer agrees to allow access to a new drug with the proviso that it gets reimbursed for those patients for whom the drug was not effective.
Pay-for performance works well when you can directly measure the outcome. When a patient with hepatitis C is treated with Harvoni (Gilead), you expect to rid this virus in almost all of the patients within 12 weeks. That’s easy to measure and....
No comments:
Post a Comment